A Three Part, First-in-human, Randomized, Double-masked, Placebo-Controlled, Safety, Tolerability and Early Efficacy Study of MGV354 in Healthy Subjects and in Patients With Ocular Hypertension or Glaucoma
Phase of Trial: Phase I/II
Latest Information Update: 29 Sep 2017
At a glance
- Drugs MGV 354 (Primary)
- Indications Open-angle glaucoma
- Focus First in man; Therapeutic Use
- Sponsors Alcon
- 27 Sep 2016 Status changed from recruiting to completed.
- 15 Aug 2016 Planned End Date changed from 1 Aug 2016 to 1 Sep 2016.
- 15 Aug 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Sep 2016.